http://www.fpnotebook.com/
Hydroxyurea
Aka: Hydroxyurea- Mechanism
- Increases production of fetal Hemoglobin (HbF)
- Indications
- Indicated for 3 or more crises per year, over age 18
- Monitoring
- Baseline
- Follow-up labs (periodically and with dose change)
- Efficacy
- Reduces Sickle Cell Crisis by 50%
- Reduces Sickle Cell Anemia mortality
| Medication Costs | ||
|---|---|---|
| Hydroxyurea (on 2/9/2012 at DrugStore.com) | ||
| Hydroxyurea 500mg Capsules | #100 for $90.99 | ($0.91/unit) |
| FPNotebook does not benefit financially from showing this medication data or their pharmacy links. This information is provided only to help medical providers and their patients see relative costs. Insurance plans negotiate lower medication prices with suppliers. Prices shown here are out of pocket, non-negotiated rates. See Needy Meds for financial assistance information. | ||
hydroxyurea (C0020402) |
|
|---|---|
| Definition (MSH) | An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase. |
| Definition (CSP) | ribonucleotide reductase inhibitor which thereby lowers intracellular dNTP pools and slows DNA replication and repair; used as antineoplastic, cell devision inhibitor, and possible chemotherapy for sickle cell anemia. |
| Definition (NCI) | A monohydroxyl-substituted urea (hydroxycarbamate) antimetabolite. Hydroxyurea selectively inhibits ribonucleoside diphosphate reductase, an enzyme required to convert ribonucleoside diphosphates into deoxyribonucleoside diphosphates, thereby preventing cells from leaving the G1/S phase of the cell cycle. This agent also exhibits radiosensitizing activity by maintaining cells in the radiation-sensitive G1 phase and interfering with DNA repair. (NCI04) |
| Definition (NCI) | An anticancer drug that belongs to the family of drugs called antimetabolites. |
| Definition (PDQ) | A monohydroxyl-substituted urea (hydroxycarbamate) antimetabolite. Hydroxyurea selectively inhibits ribonucleoside diphosphate reductase, an enzyme required to convert ribonucleoside diphosphates into deoxyribonucleoside diphosphates, thereby preventing cells from leaving the G1/S phase of the cell cycle. This agent also exhibits radiosensitizing activity by maintaining cells in the radiation-sensitive G1 phase and interfering with DNA repair. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40685&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40685&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C560" NCI Thesaurus) |
| Concepts | Organic Chemical (T109) , Pharmacologic Substance (T121) |
| MSH | D006918 |
| SnomedCT | 387314007, 56602009 |
| English | Hydroxycarbamid, Hydroxyurea, Urea, hydroxy-, hydroxyurea (medication), Hydroxycarbamide, HYDROXYUREA, Hydroxyurea [Chemical/Ingredient], hydroxycarbamide, hydroxy urea, hyd, Hydroxyurea (product), Hydroxyurea (substance), HYD, HU, hydroxyurea |
| Swedish | Hydroxiurea |
| Czech | hydroxymočovina |
| Finnish | Hydroksiurea |
| Russian | GIDROKSIMOCHEVINA, OKSIMOCHEVINA, GIDROKSIKARBAMID, ГИДРОКСИКАРБАМИД, ГИДРОКСИМОЧЕВИНА, ОКСИМОЧЕВИНА |
| Japanese | ヒドロキシ尿素, ヒドロキシウレア, ヒドロキシカルバシド, ヒドロキシカルバミド, ハイドレア |
| Spanish | hidroxicarbamida (sustancia), hidroxicarbamida, hidroxiurea (producto), hidroxiurea (sustancia), hidroxiurea, Hidroxicarbamida, Hidroxiurea |
| Italian | Idrossicarbamide, Idrossiurea |
| Polish | Hydroksymocznik |
| French | Carbamoyl-hydroxylamine, Hydroxyurée |
| German | Hydroxycarbamid, Hydroxyharnstoff |
| Portuguese | Hidroxicarbamida, Hidroxiuréia |
| Sources |
Derived from the NIH UMLS (Unified Medical Language System) |